Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

Andrea CALCAGNO; ANTONIO D'AVOLIO; Stefano BONORA

doi:10.1517/17425255.2015.1056732

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

Andrea CALCAGNO
, ANTONIO D'AVOLIO
, Stefano BONORA

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

Lingua originale	Inglese
pagine (da-a)	1167-1176
Numero di pagine	10
Rivista	Expert Opinion on Drug Metabolism and Toxicology
Volume	11
Numero di pubblicazione	7
DOI	https://doi.org/10.1517/17425255.2015.1056732
Stato di pubblicazione	Pubblicato - 2015

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

drug-to-drug interactions
pharmacodynamic
pharmacokinetic
raltegravir
resistance

Accesso al documento

10.1517/17425255.2015.1056732

https://hdl.handle.net/11579/217026

Altri file e collegamenti

handle

Cita questo

@article{90ca4738ffe74b269f828b81faadcef3,

title = "Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients",

abstract = "Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.",

keywords = "drug-to-drug interactions, pharmacodynamic, pharmacokinetic, raltegravir, resistance, drug-to-drug interactions, pharmacodynamic, pharmacokinetic, raltegravir, resistance",

author = "Andrea CALCAGNO and ANTONIO D'AVOLIO and Stefano BONORA",

year = "2015",

doi = "10.1517/17425255.2015.1056732",

language = "English",

volume = "11",

pages = "1167--1176",

journal = "Expert Opinion on Drug Metabolism and Toxicology",

issn = "1742-5255",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

AU - CALCAGNO, Andrea

AU - D'AVOLIO, ANTONIO

AU - BONORA, Stefano

PY - 2015

Y1 - 2015

N2 - Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

AB - Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.

KW - drug-to-drug interactions

KW - pharmacodynamic

KW - pharmacokinetic

KW - raltegravir

KW - resistance

KW - drug-to-drug interactions

KW - pharmacodynamic

KW - pharmacokinetic

KW - raltegravir

KW - resistance

UR - https://iris.uniupo.it/handle/11579/217026

U2 - 10.1517/17425255.2015.1056732

DO - 10.1517/17425255.2015.1056732

M3 - Article

SN - 1742-5255

VL - 11

SP - 1167

EP - 1176

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

IS - 7

ER -

Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo